StudyFinder

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study

Status: Recruiting

The goal of this study is to evaluate the combination of cabozantinib and nivolumab in people with advanced melanoma or squamous cell head and neck cancer. Researchers want to learn whether these drugs can help shrink or stabilize cancer and whether certain tumor biomarkers may help predict how well patients respond to treatment.

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosis of advanced melanoma or squamous cell head and neck cancer
• cancer has worsened during or shortly after prior PD-1 immunotherapy treatment
• able to care for yourself and perform most daily activities
• must not be pregnant or breastfeeding
• see link to clinicaltrials.gov for complete inclusion criteria
Interventions:

Procedure: Biopsy Procedure, Procedure: Biospecimen Collection, Drug: Cabozantinib S-malate, Procedure: Computed Tomography, Procedure: Magnetic Resonance Imaging, Biological: Nivolumab

Conditions:

Cancer

Keywords:

Head and Neck Squamous Cell Carcinoma, HNSCC, Melanoma

Study Contact: Kristen Nelson - knelso65@fairview.org
Principal Investigator: Puneet Cheema
Phase: PHASE2
IRB Number: MMCROC100
See this study on ClinicalTrials.gov

Back